Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Cycle Pharma scoops up beleaguered rare disease biotech
Cycle has extended a tender offer to buy all outstanding shares of Applied common stock for 8.8 cents per share at closing.
Gabrielle Masson
Dec 12, 2025 9:55am
Rezolute stock sinks 87% as hypoglycemia drug fails ph. 3 test
Dec 11, 2025 9:45am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
Akebia promises $12M for Q32’s rare kidney disease candidate
Dec 1, 2025 9:45pm
Applied lays off 46% of workforce as rare disease plans stall
Nov 20, 2025 9:10am
Analysts skeptical Applied can bring rare disease drug to market
Nov 14, 2025 5:25am
